TY - JOUR
T1 - Heart Transplantation from COVID-19–Positive Donors
T2 - A Word of Caution
AU - Castro-Varela, Alejandra
AU - Gallego-Navarro, Carlos
AU - Bhaimia, Eric
AU - Gupta, Aanchal
AU - Spencer, Philip J.
AU - Daly, Richard C.
AU - Clavell, Alfredo L.
AU - Knop, Gustavo L.
AU - Maleszewski, Joseph J.
AU - Villavicencio, Mauricio A.
AU - Cummins, Nathan W.
N1 - Publisher Copyright:
© 2023 Elsevier Inc.
PY - 2023/4
Y1 - 2023/4
N2 - Background: During the COVID-19 pandemic, efforts to maintain solid-organ transplantation have continued, including the use of SARS-CoV-2–positive heart donors. Methods: We present our institution's initial experience with SARS-CoV-2–positive heart donors. All donors met our institution's Transplant Center criteria, including a negative bronchoalveolar lavage polymerase chain reaction result. All but 1 patient received postexposure prophylaxis with anti-spike monoclonal antibody therapy, remdesivir, or both. Results: A total of 6 patients received a heart transplant from a SARS-CoV-2–positive donor. One heart transplant was complicated by catastrophic secondary graft dysfunction requiring venoarterial extracorporeal membrane oxygenation and retransplant. The remaining 5 patients did well postoperatively and were discharged from the hospital. None of the patients had evidence of COVID-19 infection after surgery. Conclusion: Heart transplants from SARS-CoV-2 polymerase chain reaction–positive donors are feasible and safe with adequate screening and postexposure prophylaxis.
AB - Background: During the COVID-19 pandemic, efforts to maintain solid-organ transplantation have continued, including the use of SARS-CoV-2–positive heart donors. Methods: We present our institution's initial experience with SARS-CoV-2–positive heart donors. All donors met our institution's Transplant Center criteria, including a negative bronchoalveolar lavage polymerase chain reaction result. All but 1 patient received postexposure prophylaxis with anti-spike monoclonal antibody therapy, remdesivir, or both. Results: A total of 6 patients received a heart transplant from a SARS-CoV-2–positive donor. One heart transplant was complicated by catastrophic secondary graft dysfunction requiring venoarterial extracorporeal membrane oxygenation and retransplant. The remaining 5 patients did well postoperatively and were discharged from the hospital. None of the patients had evidence of COVID-19 infection after surgery. Conclusion: Heart transplants from SARS-CoV-2 polymerase chain reaction–positive donors are feasible and safe with adequate screening and postexposure prophylaxis.
UR - http://www.scopus.com/inward/record.url?scp=85150778474&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85150778474&partnerID=8YFLogxK
U2 - 10.1016/j.transproceed.2023.02.048
DO - 10.1016/j.transproceed.2023.02.048
M3 - Article
C2 - 36948960
AN - SCOPUS:85150778474
SN - 0041-1345
VL - 55
SP - 533
EP - 539
JO - Transplantation proceedings
JF - Transplantation proceedings
IS - 3
ER -